All IndicationsPhase 3Phase 3Phase 2Phase 2Phase 2Phase 2Phase 2
Hidradenitis Suppurativa
6
Companies
7
Drug Programs
2
Phase 3
0
Upcoming PDUFAs
Competitors
INSM
Insmed Incorporated
Brensocatib
ABBV
AbbVie
lutikizumab
INCY
Incyte Corporation
Placebo
TXMD
TherapeuticsMD, Inc.
ATI-450
MRK
Merck
tulisokibart
ACRS
Aclaris Therapeutics, Inc.
Placebo oral tablet
INCY
Incyte Corporation
INCB054707
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| INSM Insmed Incorporated | Brensocatib | Phase 3 | — | — | — |
| ABBV AbbVie | lutikizumab | Phase 3 | — | — | — |
| INCY Incyte Corporation | Placebo | Phase 2 | — | — | — |
| TXMD TherapeuticsMD, Inc. | ATI-450 | Phase 2 | — | — | — |
| MRK Merck | tulisokibart | Phase 2 | — | — | — |
| ACRS Aclaris Therapeutics, Inc. | Placebo oral tablet | Phase 2 | — | — | — |
| INCY Incyte Corporation | INCB054707 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
2
Phase 2
5
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.